Page 4 - Wockhardt

Wockhardt Q2 net loss widens to Rs 230 million; sales at Rs 11.25 bn

India business stood at Rs 4.55 billion in the quarter as against Rs 4.52 billion in same period last year

Wockhardt up 13% after falling 33% in six weeks

The stock moved higher by 13% to Rs 503 on the BSE in intra-day trade on Monday, after hitting four-year low of Rs 437 on Friday.

HC allows Wockhardt to sell its anti-inflammatory drug till September 18

Ace Proxyvon, which is sold by the company in a tablet form, is a mixture of three salts -- aceclofenac, paracetamol and rabeprazol -- a combination which is banned

Wockhardt Q1 net loss narrows to Rs 860 mn from Rs 4.1 bn a year ago

India, US and Irish business of the company grew by 30 per cent, 20 per cent and 7 per cent respectively

Full recovery for US sales would be possible only by 2020: Wockhardt chief

Complex drugs will be less competitive than vanilla generic, but it is still going to be competitive as global players are there, says Habil Khorakiwala

Investors cheer Wockhardt on revival hopes; stock gained 41% in 2017

The drugmaker lost over Rs 20 billion of sales from the US market over the past four years

Wockhardt settles with Teva and its affiliate in London High Court

This was in relation to a supply contract for a drug named Trisenox

Wockhardt gets shareholders' nod for raising Rs 1,000 cr via QIP route

Drug firm mulling alternatives, including issuing securities to investors

Wockhardt looks for greener pastures as US FDA issues linger

Reported a Rs 196-crore net loss for 2016-17 against a profit of Rs 251 crore in the previous year

Wockhardt seeks shareholders' nod to raise up to Rs 1,000 crore

Shares of the company were trading 0.96% down at Rs 678.45 on BSE

Wockhardt seeks G-20 aid for antibiotics

This may help contain the problem of anti-microbial drug resistance

Wockhardt Shendra plant yet to get Irish regulator's nod

Wockhardt which has received US FDA warning letters on four of its plants is now facing an issue with Ireland's drug regulator.The Irish drug regulator did not recommend the renewal of good manufacturing practices (GMP) certificate of Wockhardt's Shendra plant in Maharashtra and has advised the drug maker to to take corrective actions following an inspection. This is contrary to the claim made by Wockhardt in its notification to the stock exchange on Tuesday in which it said Irish regulator has recommended the renewal of the GMP certificate.The development comes within a week of US Food and Drugs Administration issuing a warning letter to Wockhardt's manufacturing unit in the US.In an emailed response Ireland's Health Products Regulatory Authority (HPRA) said an inspection was carried at Shendra for five days till March 3 covering some non sterile dosage forms. Injectable dosage forms were not within the scope of the inspection." The company (Wockhardt) was advised that corrective ..

Wockhardt falls over 5% as US unit gets FDA warning letter

The stock dipped nearly 7% to Rs 701 on the BSE in early morning trade

Another USFDA warning for Wockhardt; US plant faces product approval freeze

Three Indian plants already under alert; Non-compliance shaves off 66% in US revenue in last 4 years

Wockhardt gains as German regulator clears Ankaleshwar plant

The stock was up 6% to Rs 713 on the BSE in early morning trade

Wockhardt's Ankaleshwar facility gets clearance from German regulator

USFDA had issued warning to the company for violating good manufacturing practice norms

Wockhardt US business, stock under pressure over regulatory action

Share of US business revenue down to 17%

USFDA issues warning letter to Wockhardt's Ankleshwar plant

USFDA has already banned the import of products from the facility into the US market since August 5, 2016

USFDA warning to Wockhardt's Ankleshwar plant over data integrity issues

Three of firm's units under import alert; FDA cites failure to check microbiological contamination

Wockhardt shares jump 3% as Daman unit gets GMP certificate from UK MHRA

On BSE, the scrip opened at Rs 699 and jumped 3.24 per cent to an early high of Rs 704.